natgillin/translations-raw huggingface dataset:
Although clinically significant hyperkalaemia has not been documented with PritorPlus, risk factors for the development of hyperkalaemia include renal insufficiency and/or heart failure, and diabetes mellitus.
Iako klinički značajna hiperkalemija nije zabilježena uz MicardisPlus, rizični faktori za razvoj hiperkalemije uključuju renalnu insuficijenciju i/ili zatajenje srca, te dijabetes melitus.
There is no experience regarding the administration of PritorPlus in patients with recent kidney transplantation.
Ne postoji iskustvo glede primjene MicardisPlusa kod bolesnika s nedavno presađenim bubregom.
The use of PritorPlus during breast feeding is not recommended.
Primjena MicardisPlusa tijekom dojenja se ne preporučuje.
Hepatic function abnormal / liver disorder
Abnormalna jetrena funkcija/poremećaj jetre
14 tablets 28 tablets 30 tablets 56 tablets 90 tablets 98 tablets 28 x 1 tablets
14 tableta 28 tableta 30 x 1 tableta 56 tableta 90 x 1 tableta 98 tableta 28 x 1 tableta
In addition, PritorPlus should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Nadalje, MicardisPlus se mora primjenjivati s oprezom kod bolesnika s oštećenom jetrenom funkcijom ili progresivnom bolesti jetre, s obzirom da manje promjene u ravnoteži tekućine i elektrolita mogu precipitirati hepatičku komu.
PritorPlus is a combination of an angiotensin II receptor antagonist, telmisartan, and a thiazide diuretic, hydrochlorothiazide.
MicardisPlus je kombinacija antagonista receptora angiotenzina II, telmisartana i tiazidskog diuretika, hidroklorotiazida.
Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 - 1.5 h after dosing.
Telmisartan: nakon peroralne primjene vršne koncetracije telmisartana postižu se 0,5-1,5 h nakon doziranja.
Co-administration of lithium and PritorPlus is not recommended (see section 4.4).
Istodobna primjena litija i MicardisPlusa se ne preporučuje (vidjeti dio 4.4).
PritorPlus is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan is used alone.
MicardisPlus se primjenjuje u liječenju visokog krvnog tlaka (esencijalna hipertenzija) kod odraslih osoba čiji krvni tlak nije dobro kontroliran uz primjenu samog telmisartana.
Precautions to be taken before handling or administering the medicinal product PritorPlus should be kept in the sealed blister due to the hygroscopic property of the tablets.
Mjere opreza koje je potrebno poduzeti prije rukovanja ili primjene lijeka MicardisPlus se mora čuvati u zatvorenom blisteru zbog higroskopnih svojstava tableta.
PritorPlus should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.
MicardisPlus ne smije se davati bolesnicima s kolestazom, bilijarnim opstruktivnim poremećajima ili teškom insuficijencijom jetre (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
Adverse reactions known to occur with each component given singly but which have not been seen in clinical trials may occur during treatment with PritorPlus.
Nuspojave za koje se zna da se pojavljuju sa svakom komponentom zasebno, ali nisu bile primijećene u kliničkim ispitivanjima mogu se pojaviti tijekom liječenja MicardisPlusom.
The effect of PritorPlus may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Učinak MicardisPlusa se može smanjiti dok uzimate NSAIL-ove (nesteroidni protuupalni lijekovi, npr. acetilsalicilatnu kiselinu ili ibuprofen).
MARKETING AUTHORISATION NUMBER(S) EU/1/02/215/015-021
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/02/213/017-023
Do not take PritorPlus
Nemojte uzimati MicardisPlus
Increased incidence of sepsis has been observed with telmisartan only, however can not be ruled out for PritorPlus.
Povećana učestalost sepse je zapažena samo uz telmisartan, ali ne može se isključiti za MicardisPlus.
PritorPlus must not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) (see section 4.3).
MicardisPlus ne smije se primjenjivati kod bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina <30 ml/min) (vidjeti dio 4.3).
Due to the hydrochlorothiazide component, markedly low blood pressure and low blood levels of potassium can also happen, which may result in nausea, sleepiness and muscle cramps and/or irregular heartbeat associated with the concomitant use of drugs such as digitalis or certain anti-arrhythmic treatments.
Zbog hidroklorotiazida kao komponente, također može doći i do izrazitijeg niskog krvnog tlaka i niskih vrijednosti kalija u krvi, što može rezultirati mučninom, pospanošću i grčevima mišića i/ili nepravilnim otkucajima srca povezanim s istodobnom primjenom lijekova kao što su digitalis ili određeni antiaritmici.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 April 2002
DATUM PRVOG ODOBRENJA / DATUM OBNOVE ODOBRENJA
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Not known:
Sijaloadenitis Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe) Nepoznato:
NAME OF THE MARKETING AUTHORISATION HOLDER Bayer (Logo)
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Boehringer Ingelheim (logo)
In patients with mild to moderate hepatic impairment the posology should not exceed PritorPlus 40 mg/12.5 mg once daily.
Kod bolesnika s blagim do umjerenim oštećenjem funkcije jetre doza ne smije prelaziti MicardisPlus 40 mg/12,5 mg jedanput dnevno.
The use of PritorPlus in children and adolescents up to the age of 18 years is not recommended.
Primjena MicardisPlusa kod djece i adolescenata ispod 18 godina starosti se ne preporučuje.
When clinically appropriate, direct change from monotherapy to the fixed combination may be considered
Kada je to klinički odogovarajuće, može se razmotriti izravni prijelaz s monoterapije na fiksnu kombinaciju.
Other medicines and PritorPlus:
Drugi lijekovi i MicardisPlus:
Adverse reactions previously reported with one of the individual components may be potential adverse reactions with PritorPlus, even if not observed in clinical trials with this product.
Nuspojave prethodno prijavljene s jednom od individualnih komponenti mogu biti potencijalne nuspojave MicardisPlusa, čak iako nisu zabilježene u kliničkim ispitivanjima ovoga lijeka.
Therefore, the use of PritorPlus is not recommended.
Stoga se ne preporučuje primjena MicardisPlusa.
How to take PritorPlus
Kako uzimati MicardisPlus
Medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid and derivatives)
Lijekovi povezani s gubitkom kalija i hipokalemijom (npr. drugi kalijuretički diuretici, laksativi, kortikosteroidi, ACTH, amfotericin, karbonoksolon, penicilin G natrij, salicilatna kiselina i derivati).
The concomitant use of PritorPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicardisPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem funkcije bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i
PritorPlus fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
MicardisPlus je kombinacija fiksne doze (40 mg telmisartana/12,5 mg hidroklorotiazida i 80 mg telmisartana/12,5 mg hidroklorotiazida), indicirana kod odraslih bolesnika čiji se krvni tlak ne može adekvatno kontrolirati samo telmisartanom.
Anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson's disease and as an aid to anaesthesia) such as atropine and biperiden.
- Antikolinergički lijekovi (lijekovi koji se primjenjuju u liječenju niza poremećaja poput grčeva probavnog sustava, grča mokraćnog mjehura, astme, bolesti kretanja, grčeva mišića, Parkinsonove bolesti te kao pomoć u anesteziji) kao što su atropin i biperiden.
Adverse reactions reported with one of the individual components may be potential adverse reactions with PritorPlus, even if not observed in clinical trials with this product.
Nuspojave prijavljene uz jednu od pojedinih komponenti mogu biti potencijalne nuspojave uz MicardisPlus, čak ako i nisu primijećene u kliničkim ispitivanjima s ovim lijekom.
Remove your PritorPlus tablet from the blister only directly prior to intake.
Tablete se vade iz blistera tek neposredno prije primjene.
PritorPlus is not indicated in patients with severe hepatic impairment.
MicardisPlus nije indiciran kod bolesnika s teškim oštećenjem funkcije jetre.
Each 40 mg/12.5 mg tablet contains 112 mg of lactose monohydrate and 169 mg sorbitol (E420).
Jedna tableta 40 mg/12,5 mg sadržava 112 mg laktoze hidrata i 169 mg sorbitola (E420).
Luxembourg / Luxemburg Bayer SA-NV
Luxembourg/Luxemburg SCS Boehringer Ingelheim Comm.V
There is no clinical experience with PritorPlus in patients with hepatic impairment.
Nema kliničkog iskustva s MicardisPlusom kod bolesnika s oštećenjem funkcije jetre.
If you have further questions on the use of this this medicine, ask your doctor or pharmacist.
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se liječniku ili ljekarniku.
PritorPlus should be kept in the sealed blister due to the hygroscopic property of the tablets.
MicardisPlus je potrebno čuvati u zatvorenom blisteru zbog higroskopskih svojstava tableta.
• PritorPlus 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Pritor 40 mg
• MicardisPlus 40 mg/12,5 mg se primjenjuje jedanput dnevno kod bolesnika čiji se krvni tlak adekvatno ne kontrolira Micardisom 40 mg
PritorPlus is also available at the dose strengths 40 mg/12.5 mg and 80 mg/12.5 mg Renal impairment
MicardisPlus je također dostupan u jačinama 40 mg/12,5 mg i 80 mg/ 12,5 mg.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Otkriveno je da telmisartan ima sličnu učinkovitost kao i ramipril u unaprijed određenom sekundarnom ishodu od kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,99 (97,5 % CI 0,90 - 1,08), p (za neinferiornost) = 0,0004], što je bio primarni cilj u referentnoj studiji HOPE (studija procjene prevencije ishoda povezanih sa srcem - engl.
2: For further description, please see sub-section “Description of selected adverse reactions” Additional information on individual components
Za dodatni opis, molimo pogledajte odlomak „Opis izabranih nuspojava“
• PritorPlus 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Pritor 80 mg
• MicardisPlus 80 mg/12,5 mg se primjenjuje jedanput dnevno kod bolesnika čiji se krvni tlak adekvatno ne kontrolira Micardisom 80 mg
PritorPlus 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by PritorPlus 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
MicardisPlus 80 mg/25 mg se primjenjuje jedanput dnevno kod bolesnika čiji se krvni tlak adekvatno ne kontrolira s MicardisPlus 80 mg/12,5 mg ili bolesnika koji su prethodno stabilizirani zasebnim terapijama telmisartana i hidroklorotiazida.
Bayer Sp. z o.o.
Boehringer Ingelheim Sp.zo.o.
Each 80 mg/12.5 mg tablet contains 112 mg of lactose monohydrate and 338 mg sorbitol (E420).
Jedna tableta 80 mg/12,5 mg sadržava 112 mg laktoze hidrata i 338 mg sorbitola (E420).
PritorPlus 80 mg/12.5 mg tablets
MicardisPlus 80 mg/12,5 mg tablete
EU/1/02/215/001 14 tablets EU/1/02/215/002 28 tablets EU/1/02/215/003 28 x 1 tablets EU/1/02/215/013 30 tablets EU/1/02/215/004 56 tablets EU/1/02/215/011 90 tablets EU/1/02/215/005 98 tablets
EU/1/02/213/001 14 tableta EU/1/02/213/002 28 tableta EU/1/02/213/003 28 x 1 tableta EU/1/02/213/013 30 x 1 tableta EU/1/02/213/004 56 tableta EU/1/02/213/011 84 tableta EU/1/02/213/014 90 x 1 tableta EU/1/02/213/005 98 tableta
INFORMATION IN BRAILLE PritorPlus 80 mg/25 mg
16. PODACI NA BRAILLEOVOM PISMU MicardisPlus 80 mg/25 mg
Possible side effects of PritorPlus:
Moguće nuspojave MicardisPlusa:
EU/1/02/215/006 14 tablets EU/1/02/215/007 28 tablets EU/1/02/215/008 28 x 1 tablets EU/1/02/215/014 30 tablets EU/1/02/215/009 56 tablets EU/1/02/215/012 90 tablets EU/1/02/215/010 98 tablets
EU/1/02/213/006 14 tableta EU/1/02/213/007 28 tableta EU/1/02/213/008 28 x 1 tableta EU/1/02/213/015 30 x 1 tableta EU/1/02/213/009 56 tableta EU/1/02/213/012 84 tableta EU/1/02/213/016 90 x 1 tableta EU/1/02/213/010 98 tableta
Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants.
Nadalje, niski krvni tlak se može pogoršati uzimanjem alkohola, barbiturata, narkotika ili antidepresiva što se može primijetiti u obliku omaglice prilikom ustajanja.
PritorPlus fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on PritorPlus 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
MicardisPlus je kombinacija fiksne doze (80 mg telmisartana/25 mg hidroklorotiazida), indicirana kod odraslih osoba čiji se krvni tlak ne može adekvatno kontrolirati s MicardisPlus 80 mg/12,5 mg (80 mg telmisartana / 12,5 mg hidroklorotiazida) ili odraslih osoba koje su prethodno stabilizirane zasebnim terapijama telmisartana i hidroklorotiazida.
NAME OF THE MEDICINAL PRODUCT PritorPlus 80 mg/25 mg tablets
NAZIV LIJEKA MicardisPlus 80 mg/25 mg tablete
INFORMATION IN BRAILLE PritorPlus 40 mg/12.5 mg
16. PODACI NA BRAILLEOVOM PISMU MicardisPlus 40 mg/12,5 mg
EU/1/02/215/015 14 tablets EU/1/02/215/016 28 tablets EU/1/02/215/017 28 x 1 tablets EU/1/02/215/018 30 tablets EU/1/02/215/019 56 tablets EU/1/02/215/020 90 tablets EU/1/02/215/021 98 tablets
EU/1/02/213/017 14 tableta EU/1/02/213/018 28 tableta EU/1/02/213/019 28 x 1 tableta EU/1/02/213/020 30 x 1 tableta EU/1/02/213/021 56 tableta EU/1/02/213/022 90 x 1tableta EU/1/02/213/023 98 tableta
- Hyponatraemia and hypochloraemic alkalosis There is no evidence that PritorPlus would reduce or prevent diuretic-induced hyponatraemia.
Ne postoje dokazi da MicardisPlus smanjuje ili sprječava hiponatremiju induciranu diureticima.
PritorPlus 80 mg/12.5 mg tablets EU/1/02/215/006-010, 012, 014
EU/1/02/213/006-010, 012, 015-016
Yellow and white oval shaped tablet of 6.2 mm engraved with the code 'H9'.
Žuto-bijele ovalne tablete duljine 6,2 mm, s utisnutim logom tvrtke i kodom 'H9'.
Dizziness or drowsiness may occasionally occur when taking PritorPlus.
Kod uzimanja MicardisPlusa mogu se povremeno pojaviti omaglica ili omamljenost.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Unit dose blister (28x1 tablets pack) or any non 7 count blister
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Blister s jediničnim dozama sa 7 ili 10 tableta ili svaki blister koji ne sadrži 7 tableta
Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes should be co-administered cautiously with PritorPlus (see section 4.5).
Ako se uz MicardisPlus istodobno primjenjuju diuretici koji štede kalij, nadomjesci kalija, ili zamjene za sol koje sadrže kalij potreban je oprez (vidjeti dio 4.5).
Some people feel dizzy or tired when taking PritorPlus.
Neke osobe mogu osjećati omaglicu ili umor tijekom primjene MicardisPlusa.
INFORMATION IN BRAILLE PritorPlus 80 mg/12.5 mg
16. PODACI NA BRAILLEOVOM PISMU MicardisPlus 80 mg/12,5 mg
Bayer A/S Tlf: +45-45 23 50 00
Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88
Low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), serious allergic reaction (e.g. hypersensitivity, anaphylactic reaction, drug rash), low blood sugar levels (in diabetic patients), upset stomach, eczema (a skin disorder), arthrosis, inflammation of the tendons, decreased haemoglobin (a blood protein), somnolence.
Niski broj trombocita (trombocitopenija), porast određenih bijelih krvnih stanica (eozinofilija), ozbiljna alergijska reakcija (npr. preosjetljivost, anafilaktička reakcija, osip pri uzimanju lijeka), niske vrijednosti šećera u krvi (kod dijabetičara), nadražaj želuca, ekcem (poremećaj kože), artroza, upala tetiva, sniženi hemoglobin (protein u krvi), pospanost.
PritorPlus 80 mg/12.5 mg tablets Each tablet contains 80 mg telmisartan and 12.5 mg hydrochlorothiazide.
MicardisPlus 80 mg/12,5 mg tablete Jedna tableta sadržava 80 mg telmisartana i 12,5 mg hidroklorotiazida.
Bayer Hispania S.L.
Boehringer Ingelheim Italia S.p.A.
Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
D-55216 Ingelheim am Rhein Njemačka
ACE inhibitors, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, cyclosporin or other medicinal products such as heparin sodium)
Lijekovi koji mogu povisiti vrijednosti kalija ili inducirati hiperkalemiju (npr. ACE inhibitori, diuretici koji štede kalij, nadomjesci kalija, zamjenske soli koje sadrže kalij, ciklosporin, ili drugi lijekovi kao što je heparin natrij).
PritorPlus 40 mg/12.5 mg tablets Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide.
MicardisPlus 40 mg/12,5 mg tablete Jedna tableta sadržava 40 mg telmisartana i 12,5 mg hidroklorotiazida.
Bayer HealthCare Tél (N° vert): +33-(0)800 87 54 54
Boehringer Ingelheim b.v. Tel: +31 (0) 800 22 55 889
Sími: +354 540 8000
Sími/Tel: +354 535 7000
NAME OF THE MEDICINAL PRODUCT PritorPlus 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
NAZIV LIJEKA MicardisPlus 80 mg/25 mg tablete telmisartan/hidroklorotiazid
PritorPlus 80 mg/25 mg tablets are yellow and white, oval-shaped, two-layer tablets engraved with the code 'H9'.
MicardisPlus 80 mg/25 mg tablete su žuto-bijele dvoslojne tablete ovalnog oblika, s urezanim logom tvrtke i oznakom „H9“.
NAME OF THE MEDICINAL PRODUCT PritorPlus 40 mg/12.5 mg tablets
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET MicardisPlus 40 mg/12,5 mg tablete
Periodic monitoring of serum potassium and ECG is recommended when PritorPlus is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics) and the following torsades de pointes inducing medicinal products (which include some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes.
Preporučuje se periodično praćenje kalija u serumu i EKG kada se MicardisPlus uzima s lijekovima na koje utječu poremećaji kalija u serumu (npr. glikozidi digitalisa, antiaritmici) i sljedećim lijekovima koji induciraju torsades de pointes (što uključuje pojedine antiaritmike), s hipokalemijom kao predisponirajućim faktorom za torsades de pointes. - skupina Ia antiaritmika (npr. kinidin, hidrokinidin, dizopiramid) - skupina III antiaritmika (npr. amiodaron, sotalol, dofetilid, ibutilid) - neki antipsihotici (npr. tioridazin, klorpromazin, levomepromazin, trifluoperazin, cijamemazin,
Sialadenitis
Astenija
PritorPlus 80 mg/12.5 mg tablets Red and white oval shaped two layer tablet of 6.2 mm engraved with the code number 'H8'.
MicardisPlus 80 mg/12,5 mg tablete Crveno-bijele dvoslojne ovalne tablete duljine 6,2 mm, s utisnutim logom tvrtke i kodom 'H8'.
PritorPlus 80 mg/25 mg tablets telmisartan/hydrochlorothiazide
MicardisPlus 80 mg/25 mg tablete telmisartan/hidroklorotiazid
Bayer Ελλάς ΑΒΕΕ Τηλ: +30 210 618 75 00
Tηλ: +30 2 10 89 06 300
PritorPlus 80 mg/12.5 mg tablets are red and white, oval-shaped, two-layer tablets engraved with the code number 'H8'.
MicardisPlus 80 mg/12,5 mg tablete su crveno-bijele dvoslojne tablete ovalnog oblika, s urezanim logom tvrtke i oznakom „H8“.
51368 Leverkusen
4.8 Nuspojave
PritorPlus is available in blisters packs containing 14, 28, 30, 56, 90 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets.
MicardisPlus je dostupan u blister pakiranjima koja sadrže 14, 28, 56, 84, ili 98 tableta, ili u blisterima s jediničnim dozama s 28 x 1, 30 x 1, ili 90 x 1 tableta.
SC Bayer SRL Tel.: +40 21 528 59 00
Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00
Pack sizes: - Blister with 14, 28, 30, 56, 90, or 98 tablets or - Perforated unit dose blisters with 28 x 1 tablets.
Veličine pakiranja: - Blister s 14, 28, 56, 84, ili 98 tableta ili - Perforirani blisteri s jediničnim dozama s 28 x 1, 30 x 1 ili 90 x 1 tableta.
PritorPlus 40 mg/12.5 mg tablets Red and white oval shaped two layer tablet of 5.2 mm engraved with the code number 'H4'.
MicardisPlus 40 mg/12,5 mg tablete Crveno-bijele dvoslojne ovalne tablete duljine 5,2 mm, s utisnutim logom tvrtke i kodom 'H4'.
PritorPlus is available in blister packs containing 14, 28, 30, 56, 90 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets
MicardisPlus je dostupan u blister pakiranjima koja sadrže 14, 28, 56, ili 98 tableta, ili u blisterima s jediničnim dozama s 28 x 1, 30 x 1, ili 90 x 1 tableta.
BATCH NUMBER Batch
KG Binger Str. 173
PritorPlus 40 mg/12.5 mg tablets are red and white, oval-shaped two-layer tablets engraved with the code number 'H4'.
MicardisPlus 40 mg/12,5 mg tablete su crveno-bijele dvoslojne tablete ovalnog oblika, s urezanim logom tvrtke i oznakom „H4“.
PritorPlus 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
MicardisPlus 40 mg/12,5 mg tablete telmisartan/hidroklorotiazid
PritorPlus 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
MicardisPlus 80 mg/12,5 mg tablete telmisartan/hidroklorotiazid
Infections and infestations
Infekcije i infestacije Nepoznato:
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Bayer AG
11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
Tel: +39-02-397 81
Тел: +359 2 958 79 98
Alfred Gera and Sons Ltd. Tel: +356-21 44 62 05
Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600
Hydrochlorothiazide exhibits linear pharmacokinetics
Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas